PMID- 24428883
OWN - NLM
STAT- MEDLINE
DCOM- 20140826
LR  - 20211021
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 13
DP  - 2014 Jan 15
TI  - Do incretins improve endothelial function?
PG  - 21
LID - 10.1186/1475-2840-13-21 [doi]
AB  - An impaired endothelial function has been recognized in the early stage of 
      atherosclerosis, and is a major factor affecting the future development of 
      cardiovascular events. Type 2 diabetes mellitus (T2DM) is widely prevalent, and 
      is one of the most important risk factors for cardiovascular disease. T2DM is 
      associated with increases in both morbidity and mortality, particularly from 
      cardiovascular disease.New therapies based on the incretin hormone and its 
      actions are now becoming widely used, and appear to offer advantages over 
      conventional therapies by keeping the body weight steady and limiting 
      hypoglycemia, while also achieving attractive glycemic control. However, there is 
      little data available about the effects of incretins on the cardiovascular 
      system.This review will focus on the effects of incretin therapies, including 
      glucagon-like peptide-1 (GLP-1) analogs and dipeptidyl peptidase (DPP)-4 
      inhibitors, on the endothelial function, and will discuss the potential 
      mechanisms underlying these effects.
FAU - Oyama, Jun-Ichi
AU  - Oyama J
AD  - Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga 
      849-8501, Japan. junoyama@cc.saga-u.ac.jp.
FAU - Higashi, Yukihito
AU  - Higashi Y
FAU - Node, Koichi
AU  - Node K
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140115
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/blood/drug therapy/physiopathology
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/physiopathology
MH  - Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
MH  - Glucagon-Like Peptide 1/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Incretins/*therapeutic use
MH  - Risk Factors
PMC - PMC3898564
EDAT- 2014/01/17 06:00
MHDA- 2014/08/27 06:00
PMCR- 2014/01/15
CRDT- 2014/01/17 06:00
PHST- 2013/12/28 00:00 [received]
PHST- 2014/01/10 00:00 [accepted]
PHST- 2014/01/17 06:00 [entrez]
PHST- 2014/01/17 06:00 [pubmed]
PHST- 2014/08/27 06:00 [medline]
PHST- 2014/01/15 00:00 [pmc-release]
AID - 1475-2840-13-21 [pii]
AID - 10.1186/1475-2840-13-21 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2014 Jan 15;13:21. doi: 10.1186/1475-2840-13-21.